Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome

2Citations
Citations of this article
20Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Berberine (BBR) is an isoquinoline alkaloid extracted from Chinese medicinal plants showing a tight correlation with gut microbiota. Polycystic ovary syndrome (PCOS) is a prevalent reproductive and endocrine disorder syndrome among women of childbearing age. Dysbiosis, the imbalance of intestinal microorganisms, is a potential factor that takes part in the pathogenesis of PCOS. Recent evidence indicates that berberine offers promise for treating PCOS. Here, we review the recent research on the interaction between berberine and intestinal microorganisms, including the changes in the structure of gut bacteria, the intestinal metabolites after BBR treatment, and the effect of gut microbiota on the bioavailability of BBR. We also discuss the therapeutic effect of BBR on PCOS in terms of gut microbiota and its potential mechanisms.

Cite

CITATION STYLE

APA

Zhu, T. W., & Li, X. L. (2023, November 1). Berberine interacts with gut microbiota and its potential therapy for polycystic ovary syndrome. Clinical and Experimental Pharmacology and Physiology. John Wiley and Sons Inc. https://doi.org/10.1111/1440-1681.13814

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free